Table 2.
Relative risk of second primary cancer by site of first primary cancer and age at first diagnosis
| 0–49 years | 50–64 years | 65+ years | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| First primary cancer | O | E | SIR | 95%CI | O | E | SIR | 95%CI | O | E | SIR | 95%CI |
| Oral Cavity & Pharynx | 403 | 61 | 6.61 | (5.94–7.28) | 1103 | 293 | 3.76 | (3.54–3.99) | 665 | 324 | 2.05 | (1.89–2.21) |
| Oesophagus | 30 | 4 | 8.03 | (4.80–11.25) | 118 | 41 | 2.89 | (2.33–3.44) | 96 | 61 | 1.57 | (1.24–1.91) |
| Stomach | 49 | 27 | 1.79 | (1.24–2.34) | 205 | 144 | 1.43 | (1.22–1.63) | 317 | 292 | 1.09 | (0.96–1.21) |
| Colorectal | 251 | 139 | 1.81 | (1.58–2.04) | 1376 | 1086 | 1.27 | (1.20–1.34) | 2814 | 2576 | 1.09 | (1.05–1.13) |
| Liver & Intrahepatic Bile Ducts | 17 | 3 | 5.39 | (2.40–8.37) | 44 | 29 | 1.50 | (1.01–1.99) | 62 | 54 | 1.16 | (0.85–1.47) |
| Pancreas | 4 | 3 | 1.14 | (0.00–2.65) | 37 | 23 | 1.61 | (1.03–2.18) | 51 | 53 | 0.97 | (0.68–1.26) |
| Larynx | 91 | 26 | 3.56 | (2.78–4.35) | 470 | 160 | 2.94 | (2.66–3.21) | 332 | 176 | 1.88 | (1.67–2.09) |
| Lung | 120 | 40 | 3.00 | (2.43–3.57) | 671 | 339 | 1.98 | (1.82–2.13) | 769 | 533 | 1.44 | (1.34–1.55) |
| Skin Melanoma | 386 | 291 | 1.33 | (1.19–1.46) | 807 | 668 | 1.21 | (1.12–1.29) | 1083 | 904 | 1.20 | (1.12–1.27) |
| Breast female | 748 | 766 | 0.98 | (0.90–1.05) | 2041 | 2023 | 1.01 | (0.96–1.05) | 2356 | 2456 | 0.96 | (0.92–1.00) |
| Cervix Uteri | 169 | 104 | 1.63 | (1.37–1.88) | 163 | 93 | 1.75 | (1.47–2.04) | 126 | 88 | 1.43 | (1.17–1.70) |
| Corpus Uteri & NOS | 90 | 54 | 1.66 | (1.29–2.03) | 581 | 460 | 1.26 | (1.16–1.37) | 650 | 576 | 1.13 | (1.04–1.22) |
| Ovary | 74 | 48 | 1.56 | (1.17–1.94) | 155 | 119 | 1.30 | (1.08–1.51) | 138 | 124 | 1.11 | (0.92–1.31) |
| Prostate | 17 | 15 | 1.15 | (0.51–1.79) | 1269 | 1656 | 0.77 | (0.72–0.81) | 4352 | 5806 | 0.75 | (0.73–0.77) |
| Testis | 239 | 172 | 1.39 | (1.21–1.58) | 86 | 64 | 1.34 | (1.03–1.64) | 22 | 13 | 1.75 | (0.91–2.59) |
| Kidney | 71 | 42 | 1.69 | (1.27–2.12) | 331 | 240 | 1.38 | (1.23–1.54) | 464 | 370 | 1.25 | (1.14–1.37) |
| Bladder | 68 | 32 | 2.10 | (1.56–2.64) | 588 | 352 | 1.67 | (1.53–1.81) | 1087 | 781 | 1.39 | (1.31–1.48) |
| Brain & Central Nerves | 51 | 25 | 2.05 | (1.43–2.66) | 43 | 35 | 1.24 | (0.83–1.65) | 19 | 19 | 0.99 | (0.48–1.50) |
| Thyroid | 152 | 102 | 1.49 | (1.24–1.74) | 191 | 129 | 1.48 | (1.26–1.70) | 158 | 121 | 1.31 | (1.09–1.53) |
| Hodgkin Lymphoma | 174 | 53 | 3.31 | (2.79–3.83) | 91 | 40 | 2.27 | (1.77–2.77) | 58 | 33 | 1.77 | (1.27–2.26) |
| Non Hodgkin Lymphoma | 162 | 84 | 1.92 | (1.61–2.23) | 472 | 337 | 1.40 | (1.27–1.53) | 689 | 532 | 1.30 | (1.20–1.40) |
| Multiple Myeloma | 14 | 11 | 1.30 | (0.50–2.11) | 85 | 75 | 1.14 | (0.88–1.40) | 194 | 171 | 1.13 | (0.96–1.30) |
| Leukaemia | 96 | 40 | 2.43 | (1.91–2.95) | 334 | 196 | 1.70 | (1.51–1.89) | 528 | 377 | 1.40 | (1.28–1.52) |
| All Cancers | 3783 | 2256 | 1.68 | (1.62–1.73) | 11,920 | 9014 | 1.32 | (1.30–1.35) | 18,090 | 17,190 | 1.05 | (1.04–1.07) |
O: number of observed cases
E: number of expected cases
SIR: standardized incidence ratio
95%CI: 95% confidence intervals